DK3999119T3 - Modificerede AVV-capsidproteiner til behandling af slidgigtsygdom - Google Patents
Modificerede AVV-capsidproteiner til behandling af slidgigtsygdom Download PDFInfo
- Publication number
- DK3999119T3 DK3999119T3 DK20740418.7T DK20740418T DK3999119T3 DK 3999119 T3 DK3999119 T3 DK 3999119T3 DK 20740418 T DK20740418 T DK 20740418T DK 3999119 T3 DK3999119 T3 DK 3999119T3
- Authority
- DK
- Denmark
- Prior art keywords
- osteoarthritis
- modified
- treatment
- capsid proteins
- avv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2023505 | 2019-07-15 | ||
| PCT/IB2020/056635 WO2021009684A1 (en) | 2019-07-15 | 2020-07-15 | Modified aav capsid proteins for treatment of arthritic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3999119T3 true DK3999119T3 (da) | 2024-10-28 |
Family
ID=68425203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20740418.7T DK3999119T3 (da) | 2019-07-15 | 2020-07-15 | Modificerede AVV-capsidproteiner til behandling af slidgigtsygdom |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220267797A1 (https=) |
| EP (1) | EP3999119B1 (https=) |
| JP (1) | JP7681277B2 (https=) |
| KR (1) | KR20220081971A (https=) |
| CN (1) | CN114502737B (https=) |
| AU (1) | AU2020314883A1 (https=) |
| BR (1) | BR112022000724A2 (https=) |
| CA (1) | CA3146791A1 (https=) |
| DK (1) | DK3999119T3 (https=) |
| ES (1) | ES2998884T3 (https=) |
| FI (1) | FI3999119T3 (https=) |
| HR (1) | HRP20241647T1 (https=) |
| HU (1) | HUE069369T2 (https=) |
| IL (1) | IL289826A (https=) |
| LT (1) | LT3999119T (https=) |
| MX (1) | MX2022000551A (https=) |
| PH (1) | PH12022550109A1 (https=) |
| PL (1) | PL3999119T3 (https=) |
| PT (1) | PT3999119T (https=) |
| RS (1) | RS66255B1 (https=) |
| SI (1) | SI3999119T1 (https=) |
| SM (1) | SMT202400486T1 (https=) |
| WO (1) | WO2021009684A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202006056RA (en) * | 2018-01-17 | 2020-07-29 | Meiragtx Uk Ii Ltd | A modified raav capsid protein for gene therapy |
| MX2024004217A (es) | 2021-10-08 | 2024-06-26 | Dyno Therapeutics Inc | Variantes de cápside y métodos de uso de estas. |
| IL313832A (en) * | 2021-12-28 | 2024-08-01 | Chengdu Origen Biotechnology Co Ltd | Modified AAV capsid protein and its use |
| TW202502803A (zh) | 2023-03-10 | 2025-01-16 | 美商戴諾治療公司 | 衣殼多肽及其使用方法 |
| CN121311235A (zh) | 2023-04-13 | 2026-01-09 | 梅里特斯基因调控有限公司 | 炎症诱导型启动子 |
| TW202525832A (zh) | 2023-08-31 | 2025-07-01 | 美商戴諾治療公司 | 衣殼多肽及其使用方法(二) |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| WO2003042361A2 (en) | 2001-11-09 | 2003-05-22 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| WO2006110689A2 (en) * | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| EP2311967B1 (en) | 2005-10-20 | 2017-09-20 | UniQure IP B.V. | Improved AAV vectors produced in insect cells |
| KR101589259B1 (ko) | 2006-06-21 | 2016-02-01 | 유니큐어 아이피 비.브이. | 곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터 |
| ES2385679T3 (es) | 2006-08-24 | 2012-07-30 | Virovek, Inc. | Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| SI3093345T1 (sl) | 2007-07-26 | 2019-08-30 | Uniqure Ip B.V. | Bakulovirusni vektorji, ki vsebujejo ponavljajoča kodirna zaporedja z različnimi kodonskimi preferencami |
| EP3257937B1 (en) | 2008-02-19 | 2022-08-03 | uniQure IP B.V. | Optimisation of expression of parvoviral rep and cap proteins in insect cells |
| WO2009154452A1 (en) | 2008-06-17 | 2009-12-23 | Amsterdam Molecular Therapeutics B.V. | Parvoviral capsid with incorporated Gly-Ala repeat region |
| WO2011112089A2 (en) | 2010-03-11 | 2011-09-15 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Mutated rep encoding sequences for use in aav production |
| PT2744895E (pt) | 2011-09-08 | 2016-02-08 | Uniqure Ip Bv | Remoção de vírus contaminantes de preparações de aav |
| WO2013174760A1 (en) * | 2012-05-25 | 2013-11-28 | Deutsches Krebsforschungszentrum | Optimized aav-vectors for high transduction rates in dendritic cells |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| IL248102B (en) * | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| CN107002096A (zh) | 2014-10-06 | 2017-08-01 | 阿罗根有限公司 | 基于aav的基因疗法 |
| FI3445773T3 (fi) * | 2016-05-13 | 2023-03-30 | 4D Molecular Therapeutics Inc | Adenoassosioituneen viruksen kapsidimuunnoksia ja niiden käyttömenetelmiä |
| CN109843306A (zh) | 2016-08-19 | 2019-06-04 | 卡琳缪恩股份有限公司 | 使用自身互补型重组腺相关病毒治疗病症的方法和组合物 |
| KR20250121159A (ko) | 2016-12-07 | 2025-08-11 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 인터류킨-1 수용체 길항제(IL-1RA) cDNA |
| US20200370039A1 (en) * | 2017-04-11 | 2020-11-26 | Ruprecht-Karls-Universitat Heidelberg | Adeno-associated virus library |
| SG11202006056RA (en) * | 2018-01-17 | 2020-07-29 | Meiragtx Uk Ii Ltd | A modified raav capsid protein for gene therapy |
-
2020
- 2020-07-15 PL PL20740418.7T patent/PL3999119T3/pl unknown
- 2020-07-15 RS RS20241346A patent/RS66255B1/sr unknown
- 2020-07-15 MX MX2022000551A patent/MX2022000551A/es unknown
- 2020-07-15 AU AU2020314883A patent/AU2020314883A1/en not_active Abandoned
- 2020-07-15 ES ES20740418T patent/ES2998884T3/es active Active
- 2020-07-15 FI FIEP20740418.7T patent/FI3999119T3/fi active
- 2020-07-15 PH PH1/2022/550109A patent/PH12022550109A1/en unknown
- 2020-07-15 LT LTEPPCT/IB2020/056635T patent/LT3999119T/lt unknown
- 2020-07-15 JP JP2022502928A patent/JP7681277B2/ja active Active
- 2020-07-15 BR BR112022000724A patent/BR112022000724A2/pt unknown
- 2020-07-15 SI SI202030519T patent/SI3999119T1/sl unknown
- 2020-07-15 HU HUE20740418A patent/HUE069369T2/hu unknown
- 2020-07-15 WO PCT/IB2020/056635 patent/WO2021009684A1/en not_active Ceased
- 2020-07-15 EP EP20740418.7A patent/EP3999119B1/en active Active
- 2020-07-15 HR HRP20241647TT patent/HRP20241647T1/hr unknown
- 2020-07-15 CA CA3146791A patent/CA3146791A1/en active Pending
- 2020-07-15 DK DK20740418.7T patent/DK3999119T3/da active
- 2020-07-15 SM SM20240486T patent/SMT202400486T1/it unknown
- 2020-07-15 US US17/627,364 patent/US20220267797A1/en active Pending
- 2020-07-15 KR KR1020227004437A patent/KR20220081971A/ko active Pending
- 2020-07-15 PT PT207404187T patent/PT3999119T/pt unknown
- 2020-07-15 CN CN202080064732.0A patent/CN114502737B/zh active Active
-
2022
- 2022-01-13 IL IL289826A patent/IL289826A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20241647T1 (hr) | 2025-02-14 |
| EP3999119A1 (en) | 2022-05-25 |
| ES2998884T3 (en) | 2025-02-24 |
| CN114502737A (zh) | 2022-05-13 |
| FI3999119T3 (fi) | 2024-11-01 |
| AU2020314883A1 (en) | 2022-03-03 |
| IL289826A (en) | 2022-03-01 |
| US20220267797A1 (en) | 2022-08-25 |
| JP2022541520A (ja) | 2022-09-26 |
| CN114502737B (zh) | 2025-05-09 |
| KR20220081971A (ko) | 2022-06-16 |
| WO2021009684A1 (en) | 2021-01-21 |
| CA3146791A1 (en) | 2021-01-21 |
| SMT202400486T1 (it) | 2025-01-14 |
| SI3999119T1 (sl) | 2025-03-31 |
| MX2022000551A (es) | 2022-05-18 |
| PH12022550109A1 (en) | 2022-12-12 |
| PT3999119T (pt) | 2024-11-25 |
| JP7681277B2 (ja) | 2025-05-22 |
| HUE069369T2 (hu) | 2025-02-28 |
| LT3999119T (lt) | 2024-12-10 |
| BR112022000724A2 (pt) | 2022-06-14 |
| RS66255B1 (sr) | 2024-12-31 |
| PL3999119T3 (pl) | 2025-02-10 |
| EP3999119B1 (en) | 2024-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3999119T3 (da) | Modificerede AVV-capsidproteiner til behandling af slidgigtsygdom | |
| DK3501542T3 (da) | Esketamin til behandling af depression | |
| IL281804A (en) | Protein purification methods | |
| SI3740222T1 (sl) | Modificiran kapsidni protein raav za gensko terapijo | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3390429T3 (da) | Modificerede kapsid-proteiner til forbedret afgivelse af parvovirus-vektorer | |
| DK3577124T3 (da) | Nukleotid hemisulfatsalt til behandlingen af hepatitis C virus | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| IL282411A (en) | Methods for analysis of viral capsid protein composition | |
| IL292625A (en) | Viruses with modified capsid proteins | |
| DK3294740T3 (da) | Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion | |
| DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
| DK3166628T3 (da) | Terapeutisk anvendelse af knoglemorfogenetiske proteiner | |
| DK3573620T3 (da) | Sammensætninger til behandling af hypertension | |
| DK3737402T5 (da) | Modificeret protein | |
| EP3990428A4 (en) | Novel molecules | |
| DK3801534T3 (da) | Behandling af fenylketonuri med sepiapterin | |
| DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
| DK4034122T3 (da) | Fremgangsmåder til behandling af hyperfenylalaninæmi | |
| HUE067058T2 (hu) | Oszteoartritisz kezelésére szolgáló dúsítási stratégiákban alkalmazható markerek | |
| DK3618845T3 (da) | Peptider til behandling af diabetes | |
| EP3656854A4 (en) | Virus for treating tumors | |
| DK3743064T3 (da) | Behandling af proteinuri | |
| DK3818078T3 (da) | Fremgangsmåder til fremstilling af rekombinante proteiner |